532 related articles for article (PubMed ID: 31543686)
1. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Lee JI; Lee HW; Lee KS
World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
3. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
[TBL] [Abstract][Full Text] [Related]
4. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
5. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
7. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
8. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
[TBL] [Abstract][Full Text] [Related]
9. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
16. Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
Chuah KH; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2020 Aug; 35(8):1404-1411. PubMed ID: 31907981
[TBL] [Abstract][Full Text] [Related]
17. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
18. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.
Cassinotto C; Boursier J; de Lédinghen V; Lebigot J; Lapuyade B; Cales P; Hiriart JB; Michalak S; Bail BL; Cartier V; Mouries A; Oberti F; Fouchard-Hubert I; Vergniol J; Aubé C
Hepatology; 2016 Jun; 63(6):1817-27. PubMed ID: 26659452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
